Glax­o­SmithK­line cel­e­brates an­oth­er Ze­ju­la win in late-line ovar­i­an can­cer — and an FDA nod for the HRD bio­mark­er

Just four months af­ter promis­ing a speedy re­view for us­ing Glax­o­SmithK­line’s Ze­ju­la in late-line ovar­i­an can­cer, the FDA has come through with an OK.

The ap­proval ar­rived just ahead of GSK’s Q3 num­bers, back­ing up R&D chief Hal Bar­ron’s lofty am­bi­tions for the PARP in­hibitor. Ze­ju­la was the crown jew­el in the phar­ma gi­ant’s $5 bil­lion ac­qui­si­tion of Tesaro, with Bar­ron el­bow­ing to en­croach on the block­buster ter­rain As­traZeneca and Mer­ck mapped with a mar­ket-lead­ing Lyn­parza in what he calls an un­der-ap­pre­ci­at­ed class.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER